Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2
Dong-Kyun Ryu, Bobin Kang, Hanmi Noh, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 578, pp. 91-96
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
Tongqing Zhou, Lingshu Wang, John Misasi, et al.
Science (2022) Vol. 376, Iss. 6591
Open Access | Times Cited: 152
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 111
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 10
Regdanvimab: First Approval
Yahiya Y. Syed
Drugs (2021) Vol. 81, Iss. 18, pp. 2133-2137
Open Access | Times Cited: 53
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Enrique Míguez‐Rey, Dasom Choi, Seungmin Kim, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 1, pp. 41-58
Open Access | Times Cited: 37
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
Juan C. Almagro, Gabriela Mellado‐Sánchez, Martha Pedraza‐Escalona, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9763-9763
Open Access | Times Cited: 29
Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD
Xiaochun Liu, Yanqing Wang, Li-shan Sun, et al.
Antiviral Research (2024) Vol. 226, pp. 105898-105898
Closed Access | Times Cited: 5
Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method
Sungbo Hwang, Seung‐Hwa Baek, Daeui Park
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 7, pp. 1771-1782
Open Access | Times Cited: 21
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Jin Yong Kim, Oana Săndulescu, Liliana Preoțescu, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 8
Open Access | Times Cited: 21
Antibody-mediated immunity to SARS-CoV-2 spike
John M. Errico, Lucas J. Adams, Daved H. Fremont
Advances in immunology (2022), pp. 1-69
Open Access | Times Cited: 21
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Aline Almeida-Oliveira, Diana Freire, A. Andrade, et al.
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 3, pp. 1194-1212
Open Access | Times Cited: 12
Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia
Ohad Benjamini, Tamar Tadmor, Abraham Avigdor, et al.
Acta Haematologica (2024) Vol. 147, Iss. 6, pp. 634-645
Open Access | Times Cited: 4
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development
Fabrizio Angius, Silvia Puxeddu, S Zaimi, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 17-17
Open Access | Times Cited: 4
Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
Karlijn van der Straten, Marit J. van Gils, Steven W. de Taeye, et al.
Frontiers in Medical Technology (2022) Vol. 4
Open Access | Times Cited: 17
Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy
Andreina Baj, Federica Novazzi, Francesca Drago Ferrante, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 2010-2015
Open Access | Times Cited: 22
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 18, pp. 6497-6553
Closed Access | Times Cited: 9
Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
Sun In Hong, Byung-Han Ryu, Kyung‐Wook Hong, et al.
Infection and Chemotherapy (2022) Vol. 54, Iss. 1, pp. 114-114
Open Access | Times Cited: 13
Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight
Mohd Imran Khan, Mohammad Hassan Baig, Tanmoy Mondal, et al.
Viruses (2021) Vol. 13, Iss. 11, pp. 2295-2295
Open Access | Times Cited: 17
A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant
Nitin Hingankar, Suprit Deshpande, Payel Das, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 4, pp. e1010465-e1010465
Open Access | Times Cited: 10
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
Tongqing Zhou, Lingshu Wang, John Misasi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 13
Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
Jacek Plichta, Piotr Kuna, Michał Panek
COVID (2022) Vol. 2, Iss. 5, pp. 599-620
Open Access | Times Cited: 9
Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
Young Rock Jang, Yoon Ju Oh, Jin Yong Kim
International Journal of Infectious Diseases (2023) Vol. 130, pp. 94-100
Open Access | Times Cited: 5
Lessons from SARS‑CoV‑2 and its variants (Review)
Ziwen Qin, Yan Sun, Jian Zhang, et al.
Molecular Medicine Reports (2022) Vol. 26, Iss. 2
Open Access | Times Cited: 8
Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
Haein Kim, Young Rock Jang, Ji Yeon Lee, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top